GUGER TECHNOLOGIES OG

Their core work

G.TEC develops brain-computer interface (BCI) hardware and software, specializing in EEG-based systems for clinical assessment, neurofeedback, and communication with patients who have disorders of consciousness. They build adaptive real-time environments that translate brain signals into actionable outputs — enabling movement restoration, patient communication, and neurological diagnosis. Beyond their core neurotechnology work, they contribute biomedical sensor expertise to large-scale materials research programs including the EU Graphene Flagship.

What they specialise in

How they've shifted over time

In 2014-2018, G.TEC focused on their core neurotechnology products — building and validating BCI systems for disorders of consciousness (COMAWARE Phase 1 and 2) and motor rehabilitation (MoveAGAIN), while entering the Graphene Flagship as a biomedical sensor partner. From 2018-2024, their portfolio shifted toward advanced materials research, with continued Graphene Flagship participation (Core2, Core3, pilot line) and a new direction in magnetoelectric nanomaterials for wireless cell stimulation (BeMAGIC). This signals a company expanding from pure BCI hardware into the underlying materials science that will define next-generation neural interfaces.

G.TEC is moving from being a BCI device company toward integrating advanced materials (graphene, magnetoelectrics) into next-generation neural interface and biosensor technologies.

How they like to work

G.TEC operates as both a project leader and a specialist contributor. They coordinated their own product-focused projects (COMAWARE, MoveAGAIN) where they drove the BCI development agenda, while joining large flagships (Graphene, 266 unique partners) as a domain-specific contributor bringing biomedical application expertise. With 24 countries in their network, they are comfortable in both small targeted consortia and massive multi-hundred-partner programs.

Extensive European network spanning 266 unique consortium partners across 24 countries, largely built through participation in the Graphene Flagship — one of the EU's largest research initiatives. Their coordinator-led projects tend to involve smaller, clinically focused consortia.

What sets them apart

G.TEC is one of very few European SMEs that both manufactures commercial BCI/EEG hardware and actively participates in fundamental materials research. This dual position — feet in the clinic and hands in the lab — means they can translate materials breakthroughs (graphene sensors, magnetoelectric stimulators) into real medical devices faster than a pure research lab. For consortium builders, they offer a rare bridge between advanced materials science and clinical neurotechnology application.

Highlights from their portfolio

• ComaWare
  Their largest project (EUR 2M) and coordinated — developed adaptive real-time environments for communicating with patients in disorders of consciousness.
• GrapheneCore2
  Part of the EU Graphene Flagship with explicit biomedical technology and sensor focus, connecting G.TEC's BCI expertise to 2D materials research.
• MoveAGAIN
  Coordinated SME-2 project combining EEG with immersive neurofeedback for movement restoration — a direct product development initiative.